<p>/PRNewswire/ -- 中國醫科大學附屬醫院（CMUH）在院長卓德揚博士的領導下，宣佈在外泌體藥物遞送方面取得重大突破，此項成就與永盛生物科技和閃耀生物醫學合作完成。在之前成功開發針對實體腫瘤的 HLA-G 靶向外泌體的基礎上，研究團隊現在將這一先進平台擴展到中央神經系統（CNS）這一高度挑戰的領域。</p>
<p>繼續閲讀</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null"/></p>
<p>由中國醫科大學附屬醫院院長卓德揚博士領導的研究團隊，與永盛生物科技和閃耀生物科技合作，共同推出了全球首個主動導航的αDAT-EV 腦靶向外泌體平台。（從左到右：閃耀生物科技副總經理李銘娟先生；中央研究院林長庚院士；中國醫科大學附屬醫院院長卓德揚博士。）</p>
<p>這一成果是全球首個主動導航的腦靶向外泌體平台——αDAT-EV，能夠跨越血腦屏障（BBB）運輸治療藥物，並精確導向與帕金森病（PD）相關的受影響神經區域。這項具有里程碑意義的研究已發表在國際領先的期刊《納米生物技術雜誌》上。</p>
<p><strong>αDAT-EV：全球首個主動導航的腦靶向外泌體藥物遞送平台</strong></p>
<p>卓博士指出，隨着全球人口老齡化，神經退行性疾病如帕金森病的發病率持續急劇上升。然而，幾十年來，神經治療藥物面臨着一個巨大的障礙：近 98% 的藥物無法有效穿越血腦屏障，嚴重限制了治療效果，並減緩了神經醫學的進展。</p>
<p>為了克服這一瓶頸，CMUH 的研究人員與閃耀生物科技合作，採用基因工程技術修改外泌體表面的抗體片段，以識別多巴胺轉運蛋白（DAT）。這一創新使得αDAT-EV 能夠主動識別和靶向多巴胺能神經元——有效地為治療藥物配備了類似 GPS 的導航系統，指導其到達病變腦區，同時提高小分子藥物的生物利用度。</p>
<p><strong>納米級</strong> <strong>“</strong> <strong>藥物指南</strong> <strong>”：用現代生物技術重新構想薑黃素</strong></p>
<p>中央研究院林長庚院士解釋説，薑黃素在傳統醫學中被譽為 “食藥同源”，以其抗氧化和抗炎特性而聞名。現代研究已證實其能夠修復神經損傷並清除病理性蛋白聚集物。儘管前景廣闊，但薑黃素的益處歷史上一直是 “可見但無法獲得”：水溶性差、代謝迅速以及無法穿越血腦屏障導致其在臨牀環境中的腦濃度微乎其微。</p>
<p>通過αDAT-EV 腦靶向平台，薑黃素現在可以被主動引導進入大腦，作為現代納米級藥物指南。這一突破體現了傳統醫學智慧與尖端生物技術的結合，併成為傳統醫學科學現代化的有力模型。</p>
<p><strong>多途徑細胞修復展示強大的轉化潛力</strong></p>
<p>閃耀生物科技副總經理李銘娟先生表示，使用裝載薑黃素的αDAT-EV 進行的臨牀前研究在細胞和動物模型中顯示出良好的治療效果，突顯了該平台作為下一代納米藥物載體的潛力：</p>
<p><strong>1. 精確靶向</strong></p>
<p>該平台顯著增強了藥物穿透血腦屏障的能力，並在與帕金森病相關的關鍵區域（包括黑質和腹側被蓋區）中富集治療藥物。</p>
<p><strong>2. 激活修復機制</strong></p>
<p>αDAT-EV 觸發細胞自噬 - 溶酶體途徑和線粒體修復機制，有效清除病理性α-突觸核蛋白聚集物，緩解疾病症狀。</p>
<p><strong>3. 免疫調節</strong></p>
<p>該治療促進了大腦小膠質細胞從促炎表型向修復表型的轉變，表明神經炎症減少。</p>
<p><strong>4. 改善運動功能</strong></p>
<p>帕金森病動物模型在運動協調方面表現出顯著恢復，突顯了該平台強大的臨牀轉化潛力。</p>
<p><strong>一個多功能的外泌體平台擴展 CNS 治療前沿</strong></p>
<p>αDAT-EV 腦靶向外泌體平台具有高度的可擴展性和擴展性。雖然最初開發用於遞送針對癌細胞的細胞毒性藥物，但現在展示了運輸神經修復治療藥物的能力。</p>
<p>這一創新為長期受血腦屏障限制的神經退行性疾病提供了變革性解決方案。展望未來，該平台可能被調整用於遞送小分子藥物、核酸療法（mRNA）或基於蛋白質的治療藥物，潛在應用於阿爾茨海默病、中風及其他 CNS 疾病，顯著推動神經學和精準醫學領域的發展。</p>
<p>在 2025 年第四季度，永盛生物科技宣佈通過股份交換交易收購閃耀生物科技 100% 的股權，導致閃耀生物科技成為全資子公司。股份交換的生效日期為 2026 年 1 月 13 日。總經理黃文良先生表示，此次收購在兩家公司技術平台和治療重點領域之間創造了強大的協同效應，加速了細胞治療向符合台灣再生醫學法和再生醫學產品法的國際競爭製藥行業的推進。</p>
<p>根據台灣的再生醫學雙重行動框架，自 2026 年 1 月 1 日起，針對危及生命或嚴重致殘疾病的再生產品可在完成 II 期臨牀試驗並證明安全性和初步療效後申請有條件的五年市場授權。此途徑顯著加速了商業化進程，併為全球老齡化社會提供了更好的治療選擇。</p>
<p>注 1：Shine Out Biotechnology 致力於開發下一代外泌體藥物遞送平台。通過利用專有的基因工程和製造技術，該公司解決了外泌體產量和靶向特異性方面的長期挑戰。Shine-On 以 “精準遞送和再生修復” 為核心，旨在成為全球外泌體基礎治療的領導者。</p>
<p>注 2：納米生物技術雜誌。</p>
<p>來源：中國醫科大學附屬醫院</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2"/></p>

<p>中國醫科大學附屬醫院（CMUH）宣佈在基於外泌體的帕金森病藥物遞送方面取得突破，與永盛生物科技和閃耀生物醫學合作。他們開發了αDAT-EV 平台，該平台能夠跨越血腦屏障運輸治療藥物，針對受影響的神經區域。這一創新使得以神曲素為代表的神經保護劑能夠有效送達大腦。前臨牀研究顯示，在增強藥物滲透、激活修復機制和改善動物模型的運動功能方面取得了良好結果。該平台在各種中樞神經系統疾病中具有潛在應用，並可擴展用於未來的治療</p>

<p>, /PRNewswire/ -- China Medical University Hospital (CMUH), under the leadership of Superintendent Dr. Cho Der-Yang, announced a major breakthrough in exosome-based drug delivery, achieved in collaboration with Ever Supreme Bio Technology and Shine-On Biomedical. Building on their prior success in developing HLA-G–targeted exosomes for solid tumors, the research team has now extended this advanced platform into the highly challenging domain of the central nervous system (CNS).</p>
<div class="lb-trans"><p>/PRNewswire/ -- 中國醫科大學附屬醫院（CMUH）在院長卓德揚博士的領導下，宣佈在外泌體藥物遞送方面取得重大突破，此項成就與永盛生物科技和閃耀生物醫學合作完成。在之前成功開發針對實體腫瘤的 HLA-G 靶向外泌體的基礎上，研究團隊現在將這一先進平台擴展到中央神經系統（CNS）這一高度挑戰的領域。</p>
</div><p>Continue Reading</p>
<div class="lb-trans"><p>繼續閲讀</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.prnewswire.com/news-releases/null" alt="" original-src="https://www.prnewswire.com/news-releases/null"/></p>
<p>The research team led by Dr. Cho Der-Yang, Superintendent of China Medical University Hospital, in collaboration with Ever Supreme Bio Technology and Shine Out Biotechnology, jointly unveiled the world’s first actively navigated αDAT-EV Brain-Targeting Exosome Platform. (From left to right: Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology; Academician Dr. LIN Jaung-Geng of Academia Sinica; Dr. Cho Der-Yang, Superintendent of China Medical University Hospital.)</p>
<div class="lb-trans"><p>由中國醫科大學附屬醫院院長卓德揚博士領導的研究團隊，與永盛生物科技和閃耀生物科技合作，共同推出了全球首個主動導航的αDAT-EV 腦靶向外泌體平台。（從左到右：閃耀生物科技副總經理李銘娟先生；中央研究院林長庚院士；中國醫科大學附屬醫院院長卓德揚博士。）</p>
</div><p>The result is a world-first, actively navigated brain-targeting exosome platform—αDAT-EV—capable of transporting therapeutic agents across the blood–brain barrier (BBB) and precisely directing them to impacted neural regions implicated in Parkinson's disease (PD). This landmark research has been published in the leading international publication Journal of Nanobiotechnology.</p>
<div class="lb-trans"><p>這一成果是全球首個主動導航的腦靶向外泌體平台——αDAT-EV，能夠跨越血腦屏障（BBB）運輸治療藥物，並精確導向與帕金森病（PD）相關的受影響神經區域。這項具有里程碑意義的研究已發表在國際領先的期刊《納米生物技術雜誌》上。</p>
</div><p><strong>αDAT-EV: The World's First Actively Navigated Brain-Targeting Exosome Drug Delivery Platform</strong></p>
<div class="lb-trans"><p><strong>αDAT-EV：全球首個主動導航的腦靶向外泌體藥物遞送平台</strong></p>
</div><p>Dr. Cho noted that as global populations age, the prevalence of neurodegenerative diseases such as Parkinson's disease continues to rise sharply. Yet for decades, neurological therapeutics have faced a formidable obstacle: nearly 98% of drugs fail to effectively cross the blood–brain barrier, severely limiting treatment efficacy and slowing progress in neurological medicine.</p>
<div class="lb-trans"><p>卓博士指出，隨着全球人口老齡化，神經退行性疾病如帕金森病的發病率持續急劇上升。然而，幾十年來，神經治療藥物面臨着一個巨大的障礙：近 98% 的藥物無法有效穿越血腦屏障，嚴重限制了治療效果，並減緩了神經醫學的進展。</p>
</div><p>To overcome this bottleneck, CMUH researchers, together with Shine Out Bio Technology, employed genetic engineering techniques to modify antibody fragments on the surface of exosomes that recognize the dopamine transporter (DAT). This innovation enables αDAT-EVs to actively identify and target dopaminergic neurons—effectively equipping therapeutic agents with a GPS-like navigation system that directs them to diseased brain regions while improving the bioavailability of small-molecule drugs.</p>
<div class="lb-trans"><p>為了克服這一瓶頸，CMUH 的研究人員與閃耀生物科技合作，採用基因工程技術修改外泌體表面的抗體片段，以識別多巴胺轉運蛋白（DAT）。這一創新使得αDAT-EV 能夠主動識別和靶向多巴胺能神經元——有效地為治療藥物配備了類似 GPS 的導航系統，指導其到達病變腦區，同時提高小分子藥物的生物利用度。</p>
</div><p><strong>A Nano-Scale</strong> <strong>&#34;</strong> <strong>Medicinal Guide</strong> <strong>&#34;: Reimagining Curcumin with Modern Biotechnology</strong></p>
<div class="lb-trans"><p><strong>納米級</strong> <strong>“</strong> <strong>藥物指南</strong> <strong>”：用現代生物技術重新構想薑黃素</strong></p>
</div><p>Academician Dr. Lin Jaung-Geng of Academia Sinica explained that curcumin, long revered in traditional medicine as a &#34;food-medicine homolog,&#34; is known for its antioxidant and anti-inflammatory properties. Modern research has confirmed its ability to repair neuronal damage at the source and clear pathological protein aggregates. Despite its promise, the benefits of curcumin have historically been &#34;visible but unattainable&#34;: poor water solubility, rapid metabolism, and inability to cross the blood–brain barrier have resulted in negligible brain concentrations in clinical settings.</p>
<div class="lb-trans"><p>中央研究院林長庚院士解釋説，薑黃素在傳統醫學中被譽為 “食藥同源”，以其抗氧化和抗炎特性而聞名。現代研究已證實其能夠修復神經損傷並清除病理性蛋白聚集物。儘管前景廣闊，但薑黃素的益處歷史上一直是 “可見但無法獲得”：水溶性差、代謝迅速以及無法穿越血腦屏障導致其在臨牀環境中的腦濃度微乎其微。</p>
</div><p>Through the αDAT-EV brain-targeting platform, curcumin can now be actively guided into the brain, functioning as a modern nano-scale medicinal guide. This breakthrough exemplifies the integration of traditional medical wisdom with cutting-edge biotechnology, and stands as a compelling model for the scientific modernization of traditional medicine.</p>
<div class="lb-trans"><p>通過αDAT-EV 腦靶向平台，薑黃素現在可以被主動引導進入大腦，作為現代納米級藥物指南。這一突破體現了傳統醫學智慧與尖端生物技術的結合，併成為傳統醫學科學現代化的有力模型。</p>
</div><p><strong>Multi-Pathway Cellular Repair Demonstrates Strong Translational Potential</strong></p>
<div class="lb-trans"><p><strong>多途徑細胞修復展示強大的轉化潛力</strong></p>
</div><p>According to Mr. Lee Ming-Juan, Vice General Manager of Shine Out Bio Technology, preclinical studies using αDAT-EVs loaded with curcumin have demonstrated promising therapeutic effects in both cellular and animal models, highlighting the platform's potential as a next-generation nano drug carrier:</p>
<div class="lb-trans"><p>閃耀生物科技副總經理李銘娟先生表示，使用裝載薑黃素的αDAT-EV 進行的臨牀前研究在細胞和動物模型中顯示出良好的治療效果，突顯了該平台作為下一代納米藥物載體的潛力：</p>
</div><p><strong>1. Precision Targeting</strong></p>
<div class="lb-trans"><p><strong>1. 精確靶向</strong></p>
</div><p>The platform significantly enhances drug penetration across the BBB and enriches therapeutic agents in key Parkinson's disease-related regions, including the substantia nigra and ventral tegmental area.</p>
<div class="lb-trans"><p>該平台顯著增強了藥物穿透血腦屏障的能力，並在與帕金森病相關的關鍵區域（包括黑質和腹側被蓋區）中富集治療藥物。</p>
</div><p><strong>2. Activation of Repair Mechanisms</strong></p>
<div class="lb-trans"><p><strong>2. 激活修復機制</strong></p>
</div><p>αDAT-EVs trigger cellular autophagy-lysosomal pathways and mitochondrial repair mechanisms, effectively clearing pathological α-synuclein aggregates and alleviating disease symptoms.</p>
<div class="lb-trans"><p>αDAT-EV 觸發細胞自噬 - 溶酶體途徑和線粒體修復機制，有效清除病理性α-突觸核蛋白聚集物，緩解疾病症狀。</p>
</div><p><strong>3.</strong> <strong>Immune Modulation</strong></p>
<div class="lb-trans"><p><strong>3. 免疫調節</strong></p>
</div><p>The treatment promotes a shift in brain microglia from a pro-inflammatory to a reparative phenotype, indicating reduced neuroinflammation.</p>
<div class="lb-trans"><p>該治療促進了大腦小膠質細胞從促炎表型向修復表型的轉變，表明神經炎症減少。</p>
</div><p><strong>4. Improved Motor Function</strong></p>
<div class="lb-trans"><p><strong>4. 改善運動功能</strong></p>
</div><p>Parkinson's disease animal models exhibited marked recovery in motor coordination, underscoring the platform's strong clinical translation potential.</p>
<div class="lb-trans"><p>帕金森病動物模型在運動協調方面表現出顯著恢復，突顯了該平台強大的臨牀轉化潛力。</p>
</div><p><strong>A Versatile Exosome Platform Expanding the CNS Therapeutic Frontier</strong></p>
<div class="lb-trans"><p><strong>一個多功能的外泌體平台擴展 CNS 治療前沿</strong></p>
</div><p>The αDAT-EV brain-targeting exosome platform is highly scalable and expandable. While initially developed to deliver cytotoxic payloads against cancer cells, it now demonstrates the ability to transport therapeutic agents for neuronal repair.</p>
<div class="lb-trans"><p>αDAT-EV 腦靶向外泌體平台具有高度的可擴展性和擴展性。雖然最初開發用於遞送針對癌細胞的細胞毒性藥物，但現在展示了運輸神經修復治療藥物的能力。</p>
</div><p>This innovation offers a transformative solution for neurodegenerative diseases long constrained by the blood–brain barrier. Looking ahead, the platform may be adapted to deliver small-molecule drugs, nucleic acid therapies (mRNA), or protein-based therapeutics, with potential applications in Alzheimer's disease, stroke, and other CNS disorders, significantly advancing the fields of neurology and precision medicine.</p>
<div class="lb-trans"><p>這一創新為長期受血腦屏障限制的神經退行性疾病提供了變革性解決方案。展望未來，該平台可能被調整用於遞送小分子藥物、核酸療法（mRNA）或基於蛋白質的治療藥物，潛在應用於阿爾茨海默病、中風及其他 CNS 疾病，顯著推動神經學和精準醫學領域的發展。</p>
</div><p>In the fourth quarter of 2025, Ever Supreme Bio Technology announced the acquisition of 100% equity in Shine Out Bio Technology through a share-exchange transaction, resulting in Shine Out becoming a wholly owned subsidiary. The effective date of the share swap is January 13, 2026. General Manager Mr. Huang Wen-Liang stated that the acquisition creates strong synergies between the two companies' technology platforms and therapeutic focus areas, accelerating the advancement of cell-based therapies into an internationally competitive pharmaceutical industry regulated under Taiwan's Regenerative Medicine Act and the Regenerative Medicine Products Act.</p>
<div class="lb-trans"><p>在 2025 年第四季度，永盛生物科技宣佈通過股份交換交易收購閃耀生物科技 100% 的股權，導致閃耀生物科技成為全資子公司。股份交換的生效日期為 2026 年 1 月 13 日。總經理黃文良先生表示，此次收購在兩家公司技術平台和治療重點領域之間創造了強大的協同效應，加速了細胞治療向符合台灣再生醫學法和再生醫學產品法的國際競爭製藥行業的推進。</p>
</div><p>Under Taiwan's Regenerative Medicine Dual-Act framework, beginning January 1, 2026, regenerative products targeting life-threatening or severely disabling diseases may apply for a conditional five-year marketing authorization upon completion of Phase II clinical trials demonstrating safety and preliminary efficacy. This pathway significantly accelerates commercialization and promises improved therapeutic options for aging societies worldwide.</p>
<div class="lb-trans"><p>根據台灣的再生醫學雙重行動框架，自 2026 年 1 月 1 日起，針對危及生命或嚴重致殘疾病的再生產品可在完成 II 期臨牀試驗並證明安全性和初步療效後申請有條件的五年市場授權。此途徑顯著加速了商業化進程，併為全球老齡化社會提供了更好的治療選擇。</p>
</div><p>Note 1: Shine Out Biotechnology is dedicated to developing next-generation exosome drug delivery platforms. Leveraging proprietary genetic engineering and manufacturing technologies, the company addresses longstanding challenges in exosome yield and targeting specificity. With &#34;precision delivery and regenerative repair&#34; at its core, Shine-On aims to become a global leader in exosome-based therapeutics.</p>
<div class="lb-trans"><p>注 1：Shine Out Biotechnology 致力於開發下一代外泌體藥物遞送平台。通過利用專有的基因工程和製造技術，該公司解決了外泌體產量和靶向特異性方面的長期挑戰。Shine-On 以 “精準遞送和再生修復” 為核心，旨在成為全球外泌體基礎治療的領導者。</p>
</div><p>Note 2: Journal of Nanobiotechnology.</p>
<div class="lb-trans"><p>注 2：納米生物技術雜誌。</p>
</div><p>SOURCE China Medical University Hospital</p>
<div class="lb-trans"><p>來源：中國醫科大學附屬醫院</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTI4Jk5ld3NJdGVtSWQ9SEs3MzEyNiZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMjgwNzQzUFJfTkVXU19VU1BSX19fX19ISzczMTI2" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=HK73126&amp;Transmission_Id=202601280743PR_NEWS_USPR_____HK73126&amp;DateId=20260128"/></p>

07:43 ET
			
			
				CMUH-Ever Supreme Team Develops World-First Brain-Targeting Exosome Delivering Curcumin Across the Blood-Brain Barrier for Parkinson's Disease

prnewswire

華夏醫藥ETF

易方達滬深300醫藥ETF

納斯達克生物科技指數 ETF - iShares Nasdaq

易方達恆生港股通創新藥ETF

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

國泰中證生物醫藥ETF

華寶中證制藥ETF

博時恆生港股通創新藥精選ETF

創新藥

博時恆生醫療保健(QDII-ETF)

美國制藥 ETF - iShares

富國恆生港股通創新藥及醫療保健ETF

招商中證生物科技主題ETF

易方達中證生物科技主題ETF

標普生物技術 ETF - SPDR

華夏上證科創板生物醫藥ETF

CMUH-Ever Supreme 團隊開發了全球首個腦靶向外泌體技術，可以將薑黃素輸送過血腦屏障，用於治療帕金森病